No E. Coli in This Lettuce: Tour the World’s Most Innovative Urban Farms
Kira Peikoff was the editor-in-chief of Leaps.org from 2017 to 2021. As a journalist, her work has appeared in The New York Times, Newsweek, Nautilus, Popular Mechanics, The New York Academy of Sciences, and other outlets. She is also the author of four suspense novels that explore controversial issues arising from scientific innovation: Living Proof, No Time to Die, Die Again Tomorrow, and Mother Knows Best. Peikoff holds a B.A. in Journalism from New York University and an M.S. in Bioethics from Columbia University. She lives in New Jersey with her husband and two young sons. Follow her on Twitter @KiraPeikoff.
By the time you reach for that head of lettuce at the grocery store, it's already probably traveled hundreds of miles and spent almost two weeks sitting in a truck.
"Food is no longer grown for human beings, it's grown for a truck to support a supply chain," says the president of Metropolis Farms in Philadelphia.
But everyone likes fresh produce, so the closer your veggies are grown to your favorite supermarket or restaurant, the better. With the recent outbreak of E.coli contaminating romaine lettuce across the United States, it's especially appealing to know that your produce has been grown nearby in a safe environment. How about a farm right on top of a grocery store in Philadelphia? Or one underground in the heart of Manhattan? Or one inside an iconic restaurant in Australia?
Hyper-local urban farming is providing some consumers with instant access to seriously fresh produce. It's also a way for restaurants and food suppliers to save on costs, eliminating the need for expensive packaging and shipping, experts say. Tour five of the world's coolest vertical farms in pictures below.
NEW YORK
Farm.One's vision is to build small indoor farms in cities around the country that provide rare herbs and produce to high-end restaurants. Their farm in the heart of Manhattan occupies 1200 square feet in a basement beneath the two-Michelin-starred restaurant Atera, which is conveniently one of their customers. All of the 20 to 25 restaurants they supply to are within a three-mile radius, making delivery possible by subway or bike.
"We have a direct connection with the chefs," says the CEO and founder Robert Laing. "For very perishable produce like herbs and leafy greens, hyper-local vertical farming works really well. It's literally dying the moment you cut it, and this is designed to be fresh."
PHILADELPHIA
"Restaurants are important," says Jack Griffin, the president of the indoor vertical Metropolis Farms in Philadelphia. "But not the most important, because they don't feed the majority of people."
Griffin is on a mission to standardize the indoor farming industry so supermarkets and communities around the world can benefit from the technology in a cost-effective and accessible way. Right now, Metropolis Farms supplies to a local grocer, Di Brunos Bros, that is less than two miles from their facility. In the future, they have plans to build a rooftop greenhouse atop a new supermarket in Philadelphia, plus indoor farms in Baltimore, Oklahoma, and as far away as India.
One advantage of their farms, says Griffin, is their proprietary technology. An adaptive lighting system allows them to grow almost any size crop, including tomatoes, cucumbers, peppers, strawberries, and even giant sunflowers.
"It's bigger than just food," he explains. "We are working on growing specialty crops like wine, chocolate, and coffee. All these plants are within reach, and we can cut the cord between supply chains that are difficult to deal with. Can you imagine if you grew Napa wines in Camden, New Jersey?"
BERLIN
GOOD BANK, in Berlin, bills itself as the world's first farm-to-table vertical restaurant. They grow their many of their own vegetables and salads onsite using farming system technology from another German company called INFARM. The latter's co-founder and CEO, Erez Galonska, cites a decline in traditional farming, an increase in urban populations, and the inefficiency of the current food system as motivation for turning to vertical farming to produce food where people actually eat and live.
"INFARM is pioneering on-demand farming services to help cities become self-sufficient in their food production, while eliminating waste and reducing their environmental impact," Galonska says.
MELBOURNE
Melbourne-based Farmwall leases indoor vertical farms the size of small bookshelves to restaurants and cafes. The farms are designed to be visually appealing, with fish tanks at the bottom supplying nutrient-rich water to the hemp media in which herbs and microgreens grow under LED lights. As part of the subscription model, urban farmers come once a week to check water levels, bring new trays of greens, and maintain the system. So far, two restaurants have signed up -- Top Paddock, in the suburb of Richmond, and Higher Ground, an internationally recognized restaurant in Melbourne.
"It's worth it to the restaurants because they get fresh produce at their fingertips and it has all the benefits of having a garden out back without any of the work," says Serena Lee, Farmwall's co-founder and chief communications officer.
The sky's the limit for future venue possibilities: nursing homes, schools, hotel lobbies, businesses, homes.
"Urban farming is never going to feed the world," Lee acknowledges. "We understand that and we're not saying it will, but when people are able to watch their food grow onsite, it triggers an awareness of local food production. It teaches people about how technology and science can work in coherence with nature to create something super-efficient, sustainable, and beautiful."
LOS ANGELES
At the restaurant Otium in Los Angeles, a peaceful rooftop garden sits atop a structure of concrete and steel that overlooks the hustle and bustle of downtown LA. Vegetables and herbs grown on the roof include Red Ribbon Sorrel, fennel fronds, borage blossoms, nasturtium, bush basil, mustard frills, mustard greens, kale, arugula, petit leaf lettuce, and mizuna. Chef Timothy Hollingsworth delights in Otium's ability to grow herbs that local purveyors don't offer, like the wild Middle Eastern Za'atar he uses on grilled steak with onions and sumac.
"I don't think this growing trend [of urban farming] is something that will be limited to a handful of restaurants," says Hollingsworth. "Every business should be concerned with sustainability and strive to protect the environment, so I think we will be seeing more and more gardening efforts throughout the country."
Whether a garden is vertical or horizontal, indoors or outdoors, on a roof or in a basement, tending to one provides not only fresh food, but intangible benefits as well.
"When you put your time and love into something," says Hollingsworth, "it really makes you respect and appreciate the produce from every stage of its life."
Kira Peikoff was the editor-in-chief of Leaps.org from 2017 to 2021. As a journalist, her work has appeared in The New York Times, Newsweek, Nautilus, Popular Mechanics, The New York Academy of Sciences, and other outlets. She is also the author of four suspense novels that explore controversial issues arising from scientific innovation: Living Proof, No Time to Die, Die Again Tomorrow, and Mother Knows Best. Peikoff holds a B.A. in Journalism from New York University and an M.S. in Bioethics from Columbia University. She lives in New Jersey with her husband and two young sons. Follow her on Twitter @KiraPeikoff.
A new type of cancer therapy is shrinking deadly brain tumors with just one treatment
Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.
But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.
How CAR-T cell therapy works
CAR-T cell therapy is a type of cancer treatment called immunotherapy, where doctors modify a patient’s own immune system specifically to find and destroy cancer cells. In CAR-T cell therapy, doctors extract the patient’s T-cells, which are immune system cells that help fight off disease—particularly cancer. These T-cells are harvested from the patient and then genetically modified in a lab to produce proteins on their surface called chimeric antigen receptors (thus becoming CAR-T cells), which makes them able to bind to a specific protein on the patient’s cancer cells. Once modified, these CAR-T cells are grown in the lab for several weeks so that they can multiply into an army of millions. When enough cells have been grown, these super-charged T-cells are infused back into the patient where they can then seek out cancer cells, bind to them, and destroy them. CAR-T cell therapies have been approved by the US Food and Drug Administration (FDA) to treat certain types of lymphomas and leukemias, as well as multiple myeloma, but haven’t been approved to treat glioblastomas—yet.
CAR-T cell therapies don’t always work against solid tumors, such as glioblastomas. Because solid tumors contain different kinds of cancer cells, some cells can evade the immune system’s detection even after CAR-T cell therapy, according to a press release from Massachusetts General Hospital. For the INCIPIENT trial, researchers modified the CAR-T cells even further in hopes of making them more effective against solid tumors. These second-generation CAR-T cells (called CARv3-TEAM-E T cells) contain special antibodies that attack EFGR, a protein expressed in the majority of glioblastoma tumors. Unlike other CAR-T cell therapies, these particular CAR-T cells were designed to be directly injected into the patient’s brain.
The INCIPIENT trial results
The INCIPIENT trial involved three patients who were enrolled in the study between March and July 2023. All three patients—a 72-year-old man, a 74-year-old man, and a 57-year-old woman—were treated with chemo and radiation and enrolled in the trial with CAR-T cells after their glioblastoma tumors came back.
The results, which were published earlier this year in the New England Journal of Medicine (NEJM), were called “rapid” and “dramatic” by doctors involved in the trial. After just a single infusion of the CAR-T cells, each patient experienced a significant reduction in their tumor sizes. Just two days after receiving the infusion, the glioblastoma tumor of the 72-year-old man decreased by nearly twenty percent. Just two months later the tumor had shrunk by an astonishing 60 percent, and the change was maintained for more than six months. The most dramatic result was in the 57-year-old female patient, whose tumor shrank nearly completely after just one infusion of the CAR-T cells.
The results of the INCIPIENT trial were unexpected and astonishing—but unfortunately, they were also temporary. For all three patients, the tumors eventually began to grow back regardless of the CAR-T cell infusions. According to the press release from MGH, the medical team is now considering treating each patient with multiple infusions or prefacing each treatment with chemotherapy to prolong the response.
While there is still “more to do,” says co-author of the study neuro-oncologist Dr. Elizabeth Gerstner, the results are still promising. If nothing else, these second-generation CAR-T cell infusions may someday be able to give patients more time than traditional treatments would allow.
“These results are exciting but they are also just the beginning,” says Dr. Marcela Maus, a doctor and professor of medicine at Mass General who was involved in the clinical trial. “They tell us that we are on the right track in pursuing a therapy that has the potential to change the outlook for this intractable disease.”
Since the early 2000s, AI systems have eliminated more than 1.7 million jobs, and that number will only increase as AI improves. Some research estimates that by 2025, AI will eliminate more than 85 million jobs.
But for all the talk about job security, AI is also proving to be a powerful tool in healthcare—specifically, cancer detection. One recently published study has shown that, remarkably, artificial intelligence was able to detect 20 percent more cancers in imaging scans than radiologists alone.
Published in The Lancet Oncology, the study analyzed the scans of 80,000 Swedish women with a moderate hereditary risk of breast cancer who had undergone a mammogram between April 2021 and July 2022. Half of these scans were read by AI and then a radiologist to double-check the findings. The second group of scans was read by two researchers without the help of AI. (Currently, the standard of care across Europe is to have two radiologists analyze a scan before diagnosing a patient with breast cancer.)
The study showed that the AI group detected cancer in 6 out of every 1,000 scans, while the radiologists detected cancer in 5 per 1,000 scans. In other words, AI found 20 percent more cancers than the highly-trained radiologists.
Scientists have been using MRI images (like the ones pictured here) to train artificial intelligence to detect cancers earlier and with more accuracy. Here, MIT's AI system, MIRAI, looks for patterns in a patient's mammograms to detect breast cancer earlier than ever before. news.mit.edu
But even though the AI was better able to pinpoint cancer on an image, it doesn’t mean radiologists will soon be out of a job. Dr. Laura Heacock, a breast radiologist at NYU, said in an interview with CNN that radiologists do much more than simply screening mammograms, and that even well-trained technology can make errors. “These tools work best when paired with highly-trained radiologists who make the final call on your mammogram. Think of it as a tool like a stethoscope for a cardiologist.”
AI is still an emerging technology, but more and more doctors are using them to detect different cancers. For example, researchers at MIT have developed a program called MIRAI, which looks at patterns in patient mammograms across a series of scans and uses an algorithm to model a patient's risk of developing breast cancer over time. The program was "trained" with more than 200,000 breast imaging scans from Massachusetts General Hospital and has been tested on over 100,000 women in different hospitals across the world. According to MIT, MIRAI "has been shown to be more accurate in predicting the risk for developing breast cancer in the short term (over a 3-year period) compared to traditional tools." It has also been able to detect breast cancer up to five years before a patient receives a diagnosis.
The challenges for cancer-detecting AI tools now is not just accuracy. AI tools are also being challenged to perform consistently well across different ages, races, and breast density profiles, particularly given the increased risks that different women face. For example, Black women are 42 percent more likely than white women to die from breast cancer, despite having nearly the same rates of breast cancer as white women. Recently, an FDA-approved AI device for screening breast cancer has come under fire for wrongly detecting cancer in Black patients significantly more often than white patients.
As AI technology improves, radiologists will be able to accurately scan a more diverse set of patients at a larger volume than ever before, potentially saving more lives than ever.